Report interim data readout from the Phase 2 study of mRNA-1647
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Aug 2020
- Due
- 30 Sep 2020
- Delivered
- 17 Sep 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects that it is on track for an interim data readout from the Phase 2 study expected in the third quarter of 2020”
What we found
Evidence strength A What the grades mean
Filings show positive interim Phase 2 mRNA-1647 data were presented at an R&D Day on September 17, 2020, before the September 30 deadline.
-
A Moderna 8-K filed 2020-10-29
“Positive interim data from Phase 2 study of CMV vaccine candidate (mRNA-1647) announced during R&D Day on September 17” ✓ confirmed on the page
-
A Moderna 8-K filed 2020-10-29
“Positive interim data from the Phase 2 study assessing the safety, reactogenicity, and immunogenicity of different dose levels of mRNA-1647 were presented at Moderna’s annual R&D Day.” ✓ confirmed on the page
-
A Moderna 10-Q filed 2020-10-30
“Positive interim data from the Phase 2 study assessing the safety, reactogenicity, and immunogenicity of different dose levels of mRNA-1647 were announced in September 2020.” ✓ confirmed on the page
Market reaction: the shares moved +1.0% against the S&P 500 over the three sessions around the disclosure (28 Oct 2020 to 2 Nov 2020). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +1796 days
- 2 versions
-
Version 1 · original · stated 5 Aug 2020
Deadline 30 Sep 2020 (“in the third quarter of 2020”) · wording expected
-
Version 2 · stated 8 Jan 2024
Deadline 31 Dec 2024 (“in 2024”) · wording expected
“The Company anticipates potential efficacy data from the study in 2024.”
-
Version 3 · stated 13 Jan 2025
Deadline 31 Dec 2025 (“in 2025”) · wording expected
“The Company remains blinded and anticipates final efficacy data from the study in 2025.”
-
Version 4 · stated 1 May 2025
Deadline 31 Aug 2025 (“in summer 2025”) · wording expected
“Moderna anticipates an interim data readout in summer 2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Interim data readout from Phase 2 CMV vaccine study (mRNA-1647)
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-MRNA-006146 · Corrections policy